Ophthalmology

The first approval for the novel device was met with acclaim in the field this year. Now, specialists want to see how their colleagues will implement it.

The meta-analysis showed a mean improvement of 15.7 ETDRS letters and central retinal thickness of 269.7 μm at 12 months.

Drs Ehsan Rahimy and Joseph M. Coney analyze the implications of clinical trial data on the management of nonproliferative diabetic retinopathy.

A panel of experts reviews data on nonproliferative diabetic retinopathy treatments from the PANORAMA, Protocol W, RISE, and RIDE studies.

A Mayo Clinic-led retrospective analysis suggests patients with T2D had an 88% greater risk of developing any diabetic retinopathy within the first 15 years of diagnosis compared to those with T1D.

Data show the HR of the risk between T2D and T2D rates of developing complications were 1.88 (95% CI, 1.13 - 3.12; P = .02) for any diabetic retinopathy.

Nancy M. Holekamp, MD, and Carl Regillo, MD, FACS, discuss the safety aspects of anti-VEGF agents when treating age-related macular degeneration.

Lloyd Clark, MD, and Jennifer I. Lim, MD, give their insight into therapy considerations when deciding to use anti-VEGF agents to treat age-related macular degeneration.

Dr Joseph M. Coney provides insight into the goals of therapy for patients with nonproliferative diabetic retinopathy.

Joseph M. Coney, MD, and Ehsan Rahimy, MD, explain the complications of nonproliferative diabetic retinopathy and emphasize the importance of early detection.

Drs Ehsan Rahimy and Diana V. Do define diabetic retinopathy and describe the symptoms.

Expert ophthalmologists debate the rationale behind choosing an anti-VEGF inhibitor for patients and the challenges involved in treatment management.

Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.

At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.

Lloyd Clark, MD, provides examples of when clinicians should refer patients with AMD to specialists, and Carl Regillo, MD, FACS, explains the typical therapy goals a specialist has for each patient.

Carl Regillo, MD, FACS, discusses diagnosing patient with age-related macular degeneration.

Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results

Nancy L. Holekamp, MD, defines age-related macular degeneration (AMD), while Jennifer I. Lim, MD, discusses signs and symptoms that are usually present in patients before diagnosis.

Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.

The Director of Retina Services at Wills Eye Hospital joins to discuss the historic FDA approval granted for a novel method of ophthalmic care: a permanent implant that allows for vision-saving formula therapy to treat the eye continually.

Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.

Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.

Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.

Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.

A geographical study shows patients in areas with lower income, education, and higher rates of ophthalmic disease may be a greater distance from a trial site.

Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.

The COLUMBUS-AMD trial suggests the investigative biosimilar could benefit patients newly diagnosed with nAMD.

A cost-based assessment of Protocol W and PANORAMA clinical data suggests diabetic retinopathy may be less costly to prevent than macular edema.

Dr. Sternberg discusses step therapy in wetAMD treatment and his opinions in favor of its use.

Bevacizumab-vikg was associated with statistically significant improvements in patient BCVA scores over a period of 12 months, according to phase 3 findings.